
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. is positioned for a positive financial outlook, driven by anticipated growth in the spine market and increasing sales from its Enabling Technologies segment, which may enhance overall profit margins. The company is seeing strong free cash flow generation, bolstered by its balance sheet, and has demonstrated impressive core spine growth in the U.S., outpacing the market at an estimated 10% increase in sales. Furthermore, the ongoing integration of NuVasive and in-sourcing manufacturing efforts are expected to contribute to gross margin expansion, with projections for EBITDA margins stabilizing at 34-35% by 2026.
Bears say
Globus Medical faces several significant risks that contribute to a negative outlook on its stock, including potential slower growth in the spine market and revenue dis-synergies arising from recent mergers with NuVasive and Nevro. The bear case scenario anticipates revenue growth slowing to low single digits, coupled with flat margins, while downside risks encompass competitive pressures, underwhelming product launches, and prolonged timelines for expansion into new musculoskeletal markets. Additionally, the company may experience a material decline in operating margins and challenges in capital investment for robotic systems, which could further jeopardize financial performance.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares